Featured Publications
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated risk
2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing
Leader A, Rebbeck T, Oh W, Patel A, Winer E, Bailey L, Gomella L, Lumpkins C, Garraway I, Aiello L, Baskin M, Cheng H, Cooney K, Ganzak A, George D, Halabi S, Hathaway F, Healy C, Kim J, Leapman M, Loeb S, Maxwell K, McNair C, Morgan T, Prindeville B, Soule H, Steward W, Suttiratana S, Taplin M, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri V. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. BMC Public Health 2024, 24: 2533. PMID: 39289635, PMCID: PMC11409532, DOI: 10.1186/s12889-024-20008-8.Peer-Reviewed Original ResearchConceptsSocioecological modelGermline testingHealthcare institutionsCancer genetic testingHereditary cancer implicationsEquity frameworkBlack malesCancer screeningReduce disparitiesBackgroundBlack menCommunity liaisonCommunity stakeholdersMixed-methods approachOvercome barriersImprovement PartnershipCommunity eventsCascade testingModified Delphi modelRate of prostate cancerGenetic testingCancer implicationsEducation programsBlack menEquitable strategiesIncreased engagementToward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, Wyatt A. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precision Oncology 2024, 8: e2300654. PMID: 38547422, PMCID: PMC10994438, DOI: 10.1200/po.23.00654.Peer-Reviewed Original ResearchConceptsClinical genomic testingGenomic testingProstate cancerTumor tissuesPoly (ADP-ribose) polymerase inhibitorsPlasma cell-free DNAHereditary cancer implicationsLow tumor fractionAdvanced prostate cancerDNA damage repair genesHealth care professionalsCell-free DNANonpathogenic variantsPatient's germlineOptimal patient careSomatic alterationsSubclonal alterationsClinical decision makingClonal hematopoiesisCare professionalsGenotyping testPoor prognosisTumor fractionPatient careCancer managementTARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
Loeb S, Keith S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Wise D, Hollifield L, Giri V. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology 2024, 8: e2300552. PMID: 38452310, PMCID: PMC10939575, DOI: 10.1200/po.23.00552.Peer-Reviewed Original ResearchConceptsGermline genetic testingDecisional conflictGenetic counselingProstate cancerPatient-drivenShortage of genetic counselorsKnowledge of cancer geneticsHereditary cancer riskReduce decisional conflictDecisional Conflict ScalePrimary outcome dataMixed-effects regression modelsDiverse patient populationsGenetic servicesClinical trial eligibilityGenetic counselorsGenetics educationPatient experienceCancer riskGermline testingAnalytical data setsCancer geneticsGermline evaluationConflict ScaleGenetic testing
2023
Usefulness of podcasts to provide public education on prostate cancer genetics
Loeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri V. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer And Prostatic Diseases 2023, 26: 772-777. PMID: 36681741, DOI: 10.1038/s41391-023-00648-4.Peer-Reviewed Original Research
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing
Loeb S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Wise D, Hollifield L, Brown L, Slater E, Pieczonka C, Gomella L, Kelly W, Trabulsi E, Handley N, Lallas C, Chandrasekar T, Mille P, Mann M, Mark J, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri V. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials 2022, 119: 106821. PMID: 35710085, DOI: 10.1016/j.cct.2022.106821.Peer-Reviewed Original ResearchConceptsKey patient-reported outcomesGermline testingPatient-reported outcomesProstate cancerGenetic counselingCollaborative care strategiesProstate cancer careTwo-armed randomizedProstate Cancer FoundationEducation/counselingGermline evaluationGOV IDENTIFIERPrimary outcomeSecondary outcomesStudy armsTarget enrollmentAshkenazi Jewish ancestryCancer careFamily historyTumor featuresCancer FoundationCare strategiesDecisional conflictUS sitesPractice settingsGermline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing
Giri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.Peer-Reviewed Original ResearchConceptsGermline testingAA menWhite menHereditary cancer assessmentStandard clinical testingCohort of menAfrican American menGermline evaluationMultivariable analysisClinical managementBorderline associationLP variantsVariant statusClinical testingGermline analysisPanel testingRate of variantsCare deliveryVariant spectrumGenetic testingCancer assessmentUncertain significanceDNA repair genesGenetic counselingAmerican menGermline testing and genetic counselling in prostate cancer
Russo J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.Peer-Reviewed Original ResearchConceptsProstate cancerCancer risk managementCancer riskGenetic testingHereditary cancer predisposition syndromesPre-test discussionUnique clinical featuresGermline pathogenic variantsPrecision medicineHealth care professionalsComplex management optionsAdditional cancer riskCancer predisposition syndromeHereditary cancer riskGenetic counsellingGermline testingMetastatic diseaseClinical featuresOptimal careMedical historyFamily historyPathogenic variantsPrecision therapyGene testingCancerGenetic testing in prostate cancer management: Considerations informing primary care
Giri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNational Comprehensive Cancer Network guidelinesProstate cancerPrimary careGenetic testingNetwork guidelinesFamily historyClinical trial optionsGermline genetic testingMetastatic prostate cancerPrimary care providersMultidisciplinary patient careProstate cancer managementRole of cliniciansHereditary cancer riskMultiple professional societiesComprehensive family historyPC survivorsGermline testingPC screeningAggressive diseasePoor outcomePC careClinical pathwayCancer managementCancer riskWhen to use germline genetic testing in prostate cancer.
Giri V. When to use germline genetic testing in prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20: 78-81. PMID: 35120087.Commentaries, Editorials and Letters
2021
Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice
Giri V, Walker A, Gross L, Trabulsi E, Lallas C, Kelly W, Gomella L, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer 2021, 20: e104-e113. PMID: 35012874, DOI: 10.1016/j.clgc.2021.11.009.Peer-Reviewed Original ResearchConceptsGermline testingFamily historyClinical practiceChronic Diseases frameworkMultiple family historyMaternal family historyCancer genetic testingMedical oncologistsAdvanced PCaPCa riskProvider interviewsAggressive PCaRadiation oncologistsPractice settingsGenetic testingLarger studyDisease frameworkClinical useOncologistsLower ratesPractice gapMenDescriptive statisticsPhiladelphia areaProvidersTesting a Prostate Cancer Educational Intervention in High-Burden Neighborhoods
Zeigler-Johnson C, Madsen R, Keith S, Glanz K, Quinn A, Giri V, Bowen E, Sauls D, Leader A. Testing a Prostate Cancer Educational Intervention in High-Burden Neighborhoods. Journal Of Racial And Ethnic Health Disparities 2021, 9: 2477-2484. PMID: 34748171, PMCID: PMC9973384, DOI: 10.1007/s40615-021-01183-5.Peer-Reviewed Original ResearchConceptsIntervention groupHealthy lifestyle (HL) control groupProstate cancer educational interventionProstate cancer risk factorsEducational interventionCancer risk factorsMixed effects regression modelsOutcome assessment measuresRisk factorsPCa knowledgeRisk menControl groupControl interventionsEthnic disparitiesLevel of knowledgePCa outcomesIntervention effectsHealth concernStudy sampleEffects regression modelsInterventionMenOutcomesBaselineDescriptive statisticsPretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs
Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly W, Calvaresi A, Handley N, Hirsch I, Izes J, Lallas C, Mann M, Mark J, Mille P, Preate D, Trabulsi E, Tsang M, Chandrasekar T, Weiner P, Gomella L, Giri V. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology 2021, 5: 1377-1386. PMID: 34589662, PMCID: PMC8462590, DOI: 10.1200/po.21.00238.Peer-Reviewed Original ResearchConceptsGermline testingProstate cancerGenetic counselingDecisional conflictComparable patient-reported outcomesHereditary cancer assessmentPatient-reported outcomesCancer genetics knowledgePCa diagnosisPractice settingsPrecision careCancer assessmentInformed consentCategorical variablesSubstantial proportionGenetic knowledgeSignificant differencesContinuous variablesHigh rateMenPractice needsDescriptive statisticsProstate oncologyOutcomesCounselingProstate Cancer Genetics: Changing the Paradigm of Care
Gomella L, Giri V. Prostate Cancer Genetics: Changing the Paradigm of Care. Urologic Clinics Of North America 2021, 48: xiii-xiv. PMID: 34210497, DOI: 10.1016/j.ucl.2021.06.001.BooksGenetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care
Mark J, McDougall C, Giri V. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics Of North America 2021, 48: 311-322. PMID: 34210487, DOI: 10.1016/j.ucl.2021.03.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingProstate cancerGenetic testing guidelinesFirst-line therapyCastration-resistant diseaseEarly-stage diseaseProstate cancer careHealth care providersGenetic test resultsPCA careCancer careCare providersScreening settingCancer implicationsPARP inhibitorsTesting guidelinesPossible roleDiseaseCareMenPractice strategiesOncologistsTestingTherapyCancerPhiladelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.
Peters C, Turner C, Chesnut G, Giri V, Gomella L, Shriver C, Dobi A. Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. Canadian Journal Of Urology 2021, 28: 10659-10667. PMID: 34129457.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBarriers and facilitators of germline genetic evaluation for prostate cancer
Loeb S, Li R, Nolasco T, Byrne N, Cheng H, Becker D, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate 2021, 81: 754-764. PMID: 34057231, DOI: 10.1002/pros.24172.Peer-Reviewed Original ResearchConceptsCoordination of careProstate cancerChronic Diseases frameworkGuideline-concordant careGermline testingMedical oncologistsPatient factorsPhysicians' knowledgePhysician educationRadiation oncologistsPractice settingsDisease frameworkThematic saturationGenetic counselingGenetic evaluationCareOncologistsRecent dataCancerConstant comparative methodInterview guidePhysiciansNumerous barriersQualitative studyInterview transcripts
2020
Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer
Loeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGermline testingLocalized diseaseMetastatic PCaFamily historyGermline evaluationMetastatic diseaseCurrent guidelinesProstate cancerCancer riskPractice settingsGenetic testingDNA mismatch repair deficiencyManagement of menProstate cancer managementFamily cancer riskEarly-stage PCaMismatch repair deficiencyHereditary cancer riskPathologic featuresHistologic featuresMedical oncologyCancer screeningPCa managementPCa riskConsensus panelPractical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.Peer-Reviewed Original ResearchConceptsGermline genetic testingProstate cancerGenetic testingNumber of patientsCritical unmet needCurrent guidelinesTesting deliveryPatientsUnmet needPrecision oncologyGenomic testingGenetic counselingGenetics providersGenetic servicesClinical workflowCancerOncologyLimited accessWorking GroupGuidelinesStandardized systemProvidersTestingClinic